Expiration date: 01/2025
Active substance: Umifenovir
Synonyms: Arpeflu
Active substance: Umifenovir
Pharmachologic effect:
It inhibits viral lipid membrane fusion with cell membranes on contact of the virus with the cell. It has interferon properties, stimulates humoral and cellular immune response, phagocytic function of macrophages, increases the body's resistance to viral infections.
Pharmacokinetics:
Rapidly absorbed from the gastrointestinal tract and distributed to organs and tissues. Cmax in the blood at a dose of 50 mg is achieved in 1.2 hours at a dose of 100 mg in 1.5 h T1 / 2 -.. 17h greatest amount of drug detected in the liver. Excreted primarily in the feces.
Description of the pharmacological actions:
It is active against influenza viruses A and B. It has long-term protective effect, reducing the symptoms of intoxication, severity of catarrhal symptoms, shortens the febrile period and the total duration of the disease. It prevents the development post- flu complications, reduces the frequency of exacerbations of chronic diseases, normalizes immunological parameters.
Testimony:
Treatment and prevention of influenza and other acute respiratory viral infections (including complicated by bronchitis and pneumonia), SARS (severe acute respiratory syndrome), chronic bronchitis, pneumonia, recurrent herpetic infection (in treatment) in the treatment of acute intestinal infection rotavirus to prevent infectious complications and the normalization of the immune status in the postoperative period.
Contraindications:
Hypersensitivity, age up to 2 years.
Side effect:
Allergic reactions (rare).
Drug Interactions:
Drug interactions with other drugs has not been described.
Dosage and administration:
Inside, and food. Single dose: Children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g (2 tablets of 0.1 g or 4 Table for.. 0.05 g).
For non-specific prevention.
In direct contact with patients with influenza and other acute respiratory viral infection: children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults 0.2 1 g once a day for 10 14 days.
During the epidemic of influenza and other acute respiratory viral infections, for the prevention of exacerbations of chronic bronchitis, recurrent herpetic infection: children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g 2 times per week for 3 weeks.
For the prevention of SARS (in contact with the patient): adults and children over 12 years: 0.2 g 1 times a day for 12-14 days.
Prevention of postoperative infectious complications: children 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g for 2 days prior to surgery, on the 2nd and 5th day after operation.
For treatment.
Influenza and other acute respiratory viral infections without complications: children 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g 4 times a day (every 6 hours) for 5 days.
Influenza and other acute respiratory viral infections with the development of complications (bronchitis, pneumonia, etc.): Children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g of 4 twice a day (every 6 hours) for 5 days, and then one single dose once a week for 4 weeks.
SARS: adults and children over 12 years - 0.2 g 2 times a day for 8-10 days.
In the complex treatment of chronic bronchitis, herpetic infection: children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g over 12 years and adults - 0.2 g 4 times a day (every 6 hours ) for 5-7 days, followed by a single dose of two times a week for 4 weeks.
Combined therapy of acute intestinal infection rotavirus etiology in children older than 2 years of age: children from 2 to 6 years - 0.05 g, 6 to 12 years - 0.1 g, over 12 years - 0.2 g 4 times a day (every 6 hours) for 5 days.
